or Try an Advanced Search...

    Technical Analysis for CARM - Carisma Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.67 9.87% 0.15
    CARM closed up 9.87 percent on Monday, July 1, 2024, on 4.14 times normal volume. It was able to find support at its 50 day moving average.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical CARM trend table...
    Date Alert Name Type % Chg
    50 DMA Support Bullish 0.00%
    MACD Bullish Centerline Cross Bullish 0.00%
    180 Bullish Setup Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Volume Surge Other 0.00%
    Wide Range Bar Range Expansion 0.00%
    Wide Bands Range Expansion 0.00%
    Above Upper BB Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Older End-of-Day Signals for CARM ...

       Recent Intraday Alerts

    Alert Time
    Up 10% about 6 hours ago
    Up 1 ATR about 6 hours ago
    60 Minute Opening Range Breakout about 6 hours ago
    Reversed from Down about 7 hours ago
    Possible Pocket Pivot about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    CARM Chart by TradingView
    Basic chart:

    Profile

    Carisma Therapeutics Inc. is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform focused on engineered macrophages, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania*, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Solid Tumors Immune System Cell Therapy Chimeric Antigen Receptor T Cell Natural Killer Cell Antigen Induced Stem Cells

    Is CARM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 28 Carisma jumps as drug discovery under Moderna deal leads to $2M payment
    Jun 27 Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
    Jun 26 Carisma Therapeutics’ solid tumour therapy obtains FDA Fast Track status
    Jun 25 Carisma Therapeutics granted FDA fast track designation for its solid tumors treatment
    Jun 25 Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
    Jun 25 Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
    Jun 13 Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
    May 30 Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
    May 16 Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
    May 14 Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation?
    See more CARM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 9.7662
    52 Week Low 0.99
    Average Volume 834,804
    200-Day Moving Average 2.41
    50-Day Moving Average 1.38
    20-Day Moving Average 1.20
    10-Day Moving Average 1.21
    Average True Range 0.16
    RSI (14) 70.06
    ADX 38.4
    +DI 39.06
    -DI 14.31
    Chandelier Exit (Long, 3 ATRs) 1.42
    Chandelier Exit (Short, 3 ATRs) 1.47
    Upper Bollinger Bands 1.52
    Lower Bollinger Band 0.87
    Percent B (%b) 1.23
    BandWidth 54.11
    MACD Line 0.00
    MACD Signal Line -0.07
    MACD Histogram 0.0727
    Fundamentals Value
    Market Cap 67.4 Million
    Num Shares 40.4 Million
    EPS -1.21
    Price-to-Earnings (P/E) Ratio -1.38
    Price-to-Sales 6.51
    Price-to-Book 1.83
    Dividend 0.00
    Dividend Yield 0.00%
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.19
    Resistance 3 (R3) 2.14 1.92 2.10
    Resistance 2 (R2) 1.92 1.79 1.94 2.07
    Resistance 1 (R1) 1.80 1.71 1.86 1.84 2.04
    Pivot Point 1.58 1.58 1.61 1.60 1.58
    Support 1 (S1) 1.45 1.44 1.51 1.50 1.30
    Support 2 (S2) 1.23 1.36 1.25 1.27
    Support 3 (S3) 1.11 1.23 1.24
    Support 4 (S4) 1.15